MX2016005955A - Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia. - Google Patents
Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia.Info
- Publication number
- MX2016005955A MX2016005955A MX2016005955A MX2016005955A MX2016005955A MX 2016005955 A MX2016005955 A MX 2016005955A MX 2016005955 A MX2016005955 A MX 2016005955A MX 2016005955 A MX2016005955 A MX 2016005955A MX 2016005955 A MX2016005955 A MX 2016005955A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- treatment
- hyperkalemia
- zirconium silicate
- microporous zirconium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/14—Base exchange silicates, e.g. zeolites
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a nuevas composiciones de silicato de zirconio microporoso que están formuladas para eliminar las toxinas, por ejemplo, iones potasio, del tracto gastrointestinal a una velocidad elevada sin causar efectos secundarios indeseables. Las formulaciones preferidas están diseñadas para evitar un aumento en pH de la orina en los pacientes y/o para evitar la posible entrada de partículas en el torrente sanguíneo del paciente. También se describe un método para preparar cristales de ZS-9 de alta pureza que exhiben un mayor nivel de capacidad de intercambio de potasio. Estas composiciones son particularmente útiles en el tratamiento terapéutico de hiperpotasemia. Estas composiciones también son útiles en el tratamiento de la enfermedad renal crónica, enfermedad vascular coronaria, diabetes mellitus y el rechazo de trasplantes.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361901886P | 2013-11-08 | 2013-11-08 | |
US201361914354P | 2013-12-10 | 2013-12-10 | |
US201461930328P | 2014-01-22 | 2014-01-22 | |
US201461930336P | 2014-01-22 | 2014-01-22 | |
US201462005484P | 2014-05-30 | 2014-05-30 | |
US201462015215P | 2014-06-20 | 2014-06-20 | |
PCT/US2014/064542 WO2015070015A1 (en) | 2013-11-08 | 2014-11-07 | Microporous zirconium silicate for the treatment of hyperkalemia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016005955A true MX2016005955A (es) | 2016-12-02 |
Family
ID=53042123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005955A MX2016005955A (es) | 2013-11-08 | 2014-11-07 | Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20160271174A1 (es) |
EP (1) | EP3065709A4 (es) |
JP (1) | JP2016535749A (es) |
KR (1) | KR20160110356A (es) |
CN (1) | CN106385795A (es) |
AU (1) | AU2014346572A1 (es) |
CA (1) | CA2929956A1 (es) |
CL (1) | CL2016001094A1 (es) |
IL (1) | IL245525A0 (es) |
MX (1) | MX2016005955A (es) |
PH (1) | PH12016500861A1 (es) |
TW (1) | TW201607544A (es) |
WO (1) | WO2015070015A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03294B (me) | 2011-02-11 | 2019-07-20 | Zs Pharma Inc | Primena cirkonijum silikata za tretman hiperkalemije |
JP2019108282A (ja) * | 2017-12-15 | 2019-07-04 | 学校法人 久留米大学 | 体内カリウム値の調整剤 |
KR20210137154A (ko) * | 2019-03-13 | 2021-11-17 | 아스트라제네카 아베 | 혈액투석 환자에서의 사용을 위한 칼륨-결합제 |
US11577014B2 (en) | 2019-07-09 | 2023-02-14 | Uop Llc | Process for removing strontium ions from bodily fluids using metallate ion exchange compositions |
US11964266B2 (en) | 2019-07-09 | 2024-04-23 | Uop Llc | Process for removing cobalt, lead, cadmium and chromium ions from bodily fluids using metallate ion exchange compositions |
US11484875B2 (en) | 2019-07-09 | 2022-11-01 | Uop Llc | Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions |
WO2021199239A1 (ja) * | 2020-03-31 | 2021-10-07 | 興和株式会社 | 包装体入り含水組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4581141A (en) * | 1978-02-27 | 1986-04-08 | Purdue Research Foundation | Dialysis material and method for removing uremic substances |
US6804800B2 (en) * | 2000-12-29 | 2004-10-12 | Intel Corporation | Method and apparatus for detecting and recovering from errors in a source synchronous bus |
JP2004075612A (ja) * | 2002-08-19 | 2004-03-11 | National Agriculture & Bio-Oriented Research Organization | 免疫機能増強剤 |
US7556799B2 (en) * | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
EP2367499A2 (en) * | 2008-12-12 | 2011-09-28 | Forsyth Dental Infirmary for Children | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy |
EP2440210A4 (en) * | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
ME03294B (me) * | 2011-02-11 | 2019-07-20 | Zs Pharma Inc | Primena cirkonijum silikata za tretman hiperkalemije |
WO2013040082A2 (en) * | 2011-09-12 | 2013-03-21 | Medtronic, Inc. | Polystyrene sulfonate resin for use with a hemodialysis system having a controlled compliance dialysis circuit |
-
2014
- 2014-11-07 EP EP14860097.6A patent/EP3065709A4/en not_active Withdrawn
- 2014-11-07 KR KR1020167015280A patent/KR20160110356A/ko not_active Application Discontinuation
- 2014-11-07 JP JP2016528081A patent/JP2016535749A/ja active Pending
- 2014-11-07 US US15/035,141 patent/US20160271174A1/en not_active Abandoned
- 2014-11-07 CN CN201480072533.9A patent/CN106385795A/zh active Pending
- 2014-11-07 WO PCT/US2014/064542 patent/WO2015070015A1/en active Application Filing
- 2014-11-07 CA CA2929956A patent/CA2929956A1/en not_active Abandoned
- 2014-11-07 US US14/536,046 patent/US20160375054A1/en not_active Abandoned
- 2014-11-07 MX MX2016005955A patent/MX2016005955A/es unknown
- 2014-11-07 AU AU2014346572A patent/AU2014346572A1/en not_active Abandoned
- 2014-11-10 TW TW103138970A patent/TW201607544A/zh unknown
-
2016
- 2016-05-06 CL CL2016001094A patent/CL2016001094A1/es unknown
- 2016-05-08 IL IL245525A patent/IL245525A0/en unknown
- 2016-05-10 PH PH12016500861A patent/PH12016500861A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20160375054A1 (en) | 2016-12-29 |
CL2016001094A1 (es) | 2016-11-11 |
JP2016535749A (ja) | 2016-11-17 |
EP3065709A1 (en) | 2016-09-14 |
KR20160110356A (ko) | 2016-09-21 |
EP3065709A4 (en) | 2017-06-14 |
PH12016500861A1 (en) | 2016-07-18 |
WO2015070015A1 (en) | 2015-05-14 |
CA2929956A1 (en) | 2015-05-14 |
US20160271174A1 (en) | 2016-09-22 |
TW201607544A (zh) | 2016-03-01 |
CN106385795A (zh) | 2017-02-08 |
AU2014346572A1 (en) | 2016-06-09 |
IL245525A0 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016204124A1 (en) | Microporous zirconium silicate for the treatment of hyperkalemia | |
PH12016500861A1 (en) | Microporous zirconium silicate for the treatment of hyperkalemia | |
PH12015500849A1 (en) | Microporous zirconium silicate for treating hyperkalemia | |
PH12016500864A1 (en) | Microporous zirconium silicate for the treatment of hyperkalemia | |
MX2021012669A (es) | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido. | |
WO2014011876A3 (en) | Zirconium silicate for treatment of hyperkalemia | |
NZ739339A (en) | Apoptosis signal-regulating kinase inhibitor | |
EA201270575A1 (ru) | Соединения | |
TW200616968A (en) | Compound having basic substituent and application thereof | |
UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
EA026385B9 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
MX2010005018A (es) | Tratamiento de complicaciones de nacimiento prematuro. | |
NO20064659L (no) | Nye kvarterniserte quinuklidin-estere | |
NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
NO20076557L (no) | Tiazolderivater og anvendelse derav | |
NZ712479A (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
NO20076559L (no) | Tiazolderivater og anvendelse derav | |
EA201490795A1 (ru) | 3,4-дизамещенное пиридиновое соединение, способы применения и содержащие его композиции | |
MA38169A1 (fr) | Ciclésonide pour le traitement d'une maladie des voies respiratoires chez les chevaux | |
EP4279925A3 (en) | Dulaglutide for the treatment of chronic kidney disease | |
WO2011089576A3 (en) | Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad) | |
NZ624714A (en) | Methods for treating gout in patient subpopulations | |
PH12016501119A1 (en) | Zirconium silicate for treating hyperkalemia without co-administering lithium | |
UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
EA201692549A1 (ru) | Безводная кристаллическая форма свободного основания 6-{2-[1-(6-метил-3-пиридазинил)-4-пиперидинил]этокси}-3-этокси-1,2-бензизоксазола |